Stage IIB Prostate Cancer Completed Phase 2 Trials for Lapatinib (DB01259)

IndicationStatusPhase
DBCOND0028879 (Stage IIB Prostate Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00103194Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate CancerTreatment